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Bone marrow mesenchymal stem cells (BMSCs), the important component and regulator of bone marrow microenvironment, give
rise to hematopoietic-supporting stromal cells and form hematopoietic niches for hematopoietic stem cells (HSCs). However, how
BMSC differentiation affects hematopoiesis is poorly understood. In this review, we focus on the role of BMSC differentiation in
hematopoiesis. We discussed the role of BMSCs and their progeny in hematopoiesis. We also examine the mechanisms that
cause differentiation bias of BMSCs in stress conditions including aging, irradiation, and chemotherapy. Moreover, the
differentiation balance of BMSCs is crucial to hematopoiesis. We highlight the negative effects of differentiation bias of BMSCs
on hematopoietic recovery after bone marrow transplantation. Keeping the differentiation balance of BMSCs is critical for
hematopoietic recovery. This review summarises current understanding about how BMSC differentiation affects hematopoiesis
and its potential application in improving hematopoietic recovery after bone marrow transplantation.
1. Introduction
A reciprocal relationship between hematopoiesis and adipo-
cyte differentiation in the bone marrow has long been
observed in experiments and in the clinic [1]. In the red mar-
row, the region of active hematopoiesis in the bone marrow
(BM), the number of lipid droplets of adipocytes is signifi-
cantly decreased (compared to yellow marrow). In contrast,
in severe myelosuppressive states such as aplastic anemia or
after irradiation, when hematopoietic tissues are damaged,
adipocytes expand their lipid contents, indicating that a fatty
change occurs in the BM [1]. Thus, bone marrow adipocytes
were thought to be a “space-filler” in the BM. In 2009,
Naveiras et al. demonstrated that bone marrow adipocytes
are negative regulators of hematopoiesis and that they inhibit
the expansion of hematopoietic cells in vivo and in vitro [2].
In the same year, Sugimura and Li proposed that the balance
between osteogenesis and adipogenesis influences hemato-
poiesis, which was the first time investigators had recognized
that the differentiation balance of BMSCs can affect bone
hematopoiesis [3]. BMSCs are important components in
the bone marrow, and both osteoblastic cells and adipo-
cytes originate from BMSCs [4]. It has been thought that
osteogenesis of BMSCs promotes hematopoiesis and that
adipocytes are negative regulators of hematopoiesis [5].
Balance between osteogenesis and adipogenesis is therefore
crucial to hematopoiesis. However, the precise mechanism
is poorly understood. Recently, large progress has been made
to understand the relationship between BMSC differentiation
and hematopoiesis. Emerging works have revealed the cen-
tral role of osteogenesis of BMSCs in bone hematopoiesis.
In addition, the role of adipogenesis in hematopoiesis has
been demonstrated. Many factors, including aging, obesity
[6], irradiation [2], and chemotherapy [7], can lead to the
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differentiation bias of BMSCs. As a result, bone hematopoie-
sis can be impaired. In this review, we would concentrate on
how BMSC differentiation affects bone hematopoiesis and
the critical role of adipo-osteogenic balance of BMSCs in
hematopoiesis. Understanding the role of BMSCs and their
progeny in hematopoiesis is important. It provides potential
targets for alleviating the negative effects of differentiation
bias of BMSCs on hematopoietic recovery. In addition,
understanding the mechanisms and factors that cause differ-
entiation bias is essential. It provides potential targets for
rescuing differentiation bias of BMSCs to promote the hema-
topoietic microenvironment for hematopoietic recovery after
bone marrow transplantation.
2. Bone Marrow Mesenchymal Stem Cells and
the Hematopoietic Microenvironment
Mesenchymal stem cells (MSCs) are a population of adult
stem cells. Although they were first found in the bone mar-
row and were therefore once termed “marrow stromal cells,”
they have since been identified in many tissues such as the
umbilical cord and adipose tissue. In vitro, MSCs have the
capacity to differentiate into different tissue lineages, and as
a result of this property, they may have important roles in
regenerative medicine [8]. In vivo, BMSCs are able to differ-
entiate into fat, cartilage, bone, and most of the stromal cells
in the bone marrow, thus playing an important role in
maintaining hematopoietic stem cells, regulating the hema-
topoietic microenvironment, and serving a crucial function
in the life-long turnover and growth of bone [4].
2.1. Potential Markers of BMSCs. In vitro, BMSCs were
shown to support long-term hematopoiesis [9]. In vivo,
transplants of bone marrow stromal cells into a heterotopic
site resulted in bone formation and local hematopoiesis
[10]. These early studies indicated the important hematopoi-
etic support capacity of BMSCs. However, there was no
specific marker that can be used to identify them in that time.
As a result, mechanisms on how BMSCs regulate hematopoi-
esis were poorly understood. Luckily, several markers,
including CD146 in human [11], CXCL12 [12], Nestin [13],
leptin receptor [14], and Prx-1 [15] in mice, were shown to
be markers of BMSCs. BM cells with each of these markers
have the proposed characteristics of BMSCs. They are able
to give rise to osteoblast cells and express factors and cyto-
kines that support HSCs. Theoretically, these markers that
identify BMSCs in vivo make it possible to study the mecha-
nisms on how BMSCs regulate hematopoiesis. Using some of
these markers, BMSCs were shown to predominantly localize
around blood vessels and sinusoids in the BM [11, 13].
2.2. Hematopoietic Regulation by BMSCs. Using kinds of
transgenic mice, BMSCs turn out to be critical for the main-
tenance of HSCs [16]. BMSCs are the major source of SCF
and CXCL12, which is critical for maintenance of HSCs
[17]. Deletion of CXCL12-abundant reticular cells (CAR)
not only significantly decreased the amount of SCF and
CXCL12 but also deleted the HSC in the BM [17]. BMSCs
also express Nestin-GFP+ transgene, and ablation of
Nestin-GFP+ BM cells deleted the HSCs in the BM and
increased HSCs in the spleen [13]. Moreover, conditional
deletion of SCF from LepR-Cre stromal cells [14] or condi-
tional deletion of CXCL12 from Prx-1-Cre cells was also
shown to eliminate HSCs in the BM [18]. These emerging
studies suggested that BMSCs serve as important niche
component supporting HSCs.
Within the total cell population of BMSCs, a distinct
subgroup of BMSCs have different functions in regulating
HSCs [19]. A small subgroup of BMSCs (NG2+ LepR− cells),
which belong to small arterioles close to the endosteal region,
was shown to contribute to arteriolar niches maintaining
HSC quiescence. The other part of BMSCs (NG2− LepR+
cells), which are adjacent to sinusoids, is thought to form
perisinusoidal niches proliferating HSCs in the BM. Acti-
vation of HSC cell cycle changed the distribution of HSCs
from these two kinds of niches. Also, conditional depletion
of cell expressing NG2 induced HSC cycling [19]. These
data revealed the important role of BMSCs themselves in
BM hematopoiesis.
In addition, it is believed that the marrow stromal cells
generated by BMSCs are crucial to bone hematopoiesis
[20]. Marrow stromal cells, including osteoblasts, adipocytes
derived from BMSCs, are thought to form the hematopoietic
microenvironment [21]. The differentiation of BMSCs,
especially to osteogenic and adipogenic lineages, is crucial
to bone hematopoiesis.
3. Osteogenic Differentiation of Bone Marrow
Mesenchymal Stem Cells and Hematopoiesis
At different stages of development, the progenitors that
contribute to bone formation are very different. During the
embryonic stage of a mouse, the nascent bone tissue derives
from Osterix+ progenitors [22]. Given that bone anlagen
derives from different germ layers [23], it is proposed that
these progenitors have more than one developmental origin,
including mesoderm [23] and ectomesenchyme of the neural
crest [24]. However, during the adult life of a mouse, LepR+
BMSCs are the major source of the bone [25]. In this review,
we mainly discuss the BMSCs in adult.
Adult BMSCs can differentiate into many cell types such
as adipocytes, osteoblasts, and chondrocytes in the bone.
Many methods mimicking these processes in vitro have been
developed. For example, osteogenic differentiation can be
induced in vitro by bone morphogenetic proteins (BMPs)
[26] or by a differentiation cocktail [27]. It has been recog-
nized that Runt-related transcription factor 2 (Runx2) is
the key transcription factor in osteogenic differentiation, as
activation of Runx2 is considered an initiating event in
osteogenic commitment of MSCs [28]. Runx2 can interact
with the cis-element on the osteocalcin gene and cause the
transcription of several osteoblast-specific genes, inducing
osteogenesis in vivo and in vitro [29].
Osteoblast lineage cells are thought to promote hemato-
poiesis. In an early study, osteoblasts were shown to support
the expansion of hematopoietic progenitors in vitro [30].
Using transgenic mice, Calvi et al. demonstrated the posi-
tive correlation between osteoblast lineage cells and HSC
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number [31]. Conversely, ablation of osteoblast lineage
cells results in a severe decrease in the number of HSCs
[32]. These results indicate that osteoblast lineage cells
can increase the number of HSCs, thus influencing hema-
topoiesis. Further studies have established the central role
of osteoblast lineage cells in bone hematopoiesis. Distinct
cell types in different stages of osteogenic differentiation
form distinct niches for hematopoietic cell (Figure 1). In
general, osteoblast lineage cells include osteoprogenitors,
osteoblasts, and osteocytes [33].
3.1. Osteoprogenitors Support B Cell Differentiation. Osteo-
progenitors are indispensable to B cell differentiation. B cells
are derived from CLP in the BM. The developing B cells can
be divided into several discrete cell population: prepro-B,
pro-B, pre-B, immature B, and mature B [34]. Early studies
have demonstrated that genetic disruption of the osteogenic
lineage decreased mature B cells in animals [18, 35], indicat-
ing that the osteogenic lineage may participate in the
development of B cell. Using transgenic mouse, Yu et al.
demonstrated that Osx+ osteoprogenitors in the BM are
essential for B cell differentiation. In the early stage of B
cell differentiation, prepro-B to pro-B transition depends
on Osx+ osteoprogenitor-derived IL-7 [36]. Specifically,
although IL-7 can also be produced by other BM compo-
nents, Osx+ osteoprogenitor-derived IL-7 is indispensable
for B cell development. Deletion of Gsα in Osx+ osteopro-
genitors resulted in a block of prepro-B to pro-B transition
[35]. However, expression of IL-7 in osteogenic lineage cells
turned out to rescue B cell development, indicating a critical
role of Osx+ osteoprogenitors in B cell development [37].
Meanwhile, pro-B to pre-B transition depends on the
Osx+ osteoprogenitor-derived IGF-1 [36]. Deletion of Osx+
osteoprogenitors blocked not only the prepro-B to pro-B
transition but also the pro-B to pre-B transition. The addition
of IL-7 rescued the prepro-B to pro-B transition, while the
addition of IGF-1 rescued the pro-B to pre-B transition
[36]. Furthermore, Osx+ osteoprogenitors turned out to
regulate B lymphocyte mobilization. Specifically, deletion of
PPR in osteoprogenitors led to reduced number of B cell
progenitors in the BM [33]. However, BMmature B lympho-
cytes increased. This was associated with the overexpression
of VCAM1 caused by PPR deficiency. Taken together, Osx+
osteoprogenitors is indispensable for B cell differentiation.
The deficiency of Osx+ osteoprogenitor could impair B cell
maturation and adaptive immune response [33]. PTH signal-
ing in osteoprogenitors, instead of osteoblasts and osteocytes,
is indispensable for B cell differentiation [33].
3.2. Osteoblast Supports T Cell Differentiation and HSC
Function. The process of T cell differentiation includes two
stages: prethymic stage and thymic stage [38]. First, BM
HSCs give rise to thymus-seeding progenitor of T cells, which
migrate to thymus. Second, thymus-seeding progenitors
enter thymus and differentiate to naive T cells. After HSCT,
the prethymic stage is critical for hematopoietic recovery
because the number of thymus-seeding cells is a limit factor
for T cell recovery [39].
In prethymic stage, mature osteoblast is indispensable for
the production of thymus-seeding progenitors of T cell.
DLL4, a Notch ligand expressed in mature osteoblast, is
essential for the production of this cell. Deletion of OCN+
mature osteoblast decreased common lymphoid progenitors
(CLPs) with T cell potential in the BM and downstream
T progenitors in the thymus. Also, conditional deletion of
DLL4 in OCN+mature osteoblast resulted in similar changes.
And recombinant DLL4 was shown to rescue T cell develop-
ment in OCN+ cell-deleted animals.
These data indicate that OCN+ mature osteoblasts in the
BM provide important molecule for T cell development [40].
Moreover, it was reported that osteoblasts may have a
role in HSC function. In early studies, the positive correlation
between osteoblast lineage cells and HSC number was
demonstrated [31]. Ablation of osteoblast cells led to deletion
of HSCs in the BM [32]. Although the methods used to
manipulate osteoblast lineage cells were not specific, these
initial studies suggested that osteoblasts may have a role
in HSC regulation. But this idea is controversial.
In osteoblast lineage cells, mature osteoblast appears to
be no longer a direct regulator of HSC. Deletion of OCN+
mature osteoblasts, while impairing the generation of T
progenitors, did not affect the HSC number in the BM [40].
Also, the expansion of mature osteoblasts turned to even
reduce HSC number in the BM [41]. These data indicated
that mature osteoblasts may be not a direct regulator of
HSC. In another review, Morrison and Scadden believed that
mature osteoblasts are essential to HSC function but not nec-
essary to regulate HSCs [42].
Despite the fact that these studies [40, 41] excluded the
direct role of mature osteoblasts in HSC regulation, they
could not rule out the role of other osteoblast lineage compo-
nent in HSC regulation. OCN reporter used in these studies
could target mature osteoblast but not immature osteoblast
[43]. The expression of OCN in immature osteoblasts was
shown to be low [44]. Recent studies have demonstrated that
hematopoiesis-enhancing activity (HEA) of osteoblast corre-
lated with the expression of Runx2 and osteoblast maturation
[44]. Immature osteoblasts express high level of Runx2 and
seem to mediate HEA. These cells express CD166, which
declines with maturation of osteoblasts and correlates with
high HEA [45]. In CD166−/− mice, LT-HSC engrafting was
significantly impaired under stress condition, suggesting that
immature osteoblasts may regulate HSCs via CD166, and
CD166 can be a target to enhance HSC function [46].
Taken together, the immature osteoblast may play a role
in HSC expansion and maintenance. However, this popu-
lation still remains incompletely defined. Developing
specific marker that targets immature osteoblasts is neces-
sary for further studies.
3.3. Osteocytes Are Indispensable for Lymphopoiesis and
HSC Mobilization. Over the decades, the function of oste-
ocytes has been widely studied. Osteocytes account for
more than 90% of the bone cells. They are essential for
bone health and nonbone organs [47]. Although most of
the osteocytes are embedded in the bone, they were found
to regulate hematopoiesis. In osteocyte-deleted mice, both
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B and T lymphopoiesis were severely impaired. Deletion of
osteocytes did not affect the BM cellularity, but the early
stage of B cell development was blocked. B cell progeni-
tors, including pro-B, pre-B, and immature B, were greatly
reduced in osteocyte-less mice. Lack of lymphoid-
supporting stroma in the BM was proposed to be the
cause of B lymphopenia [48]. In comparison, the thymic
atrophy was considered as the major cause of T lympho-
penia in osteocyte-less mice. The thymus of osteocyte-
less mice failed to support T cell differentiation in vivo.
These data indicate that osteocytes are required for
lymphoid-supporting stroma in the BM and thymus [48].
However, the precise mechanism is still largely unknown.
Osteocytes also regulate HSPC mobilization. In the clinic,
G-CSF is used to mobilize HSPCs. However, in osteocyte-
less mice, G-CSF failed to mobilize HSPCs into circulation,
indicating that osteocytes have an essential role in G-CSF-
induced HSPC mobilization [49].
These studies established the central role of osteoblast
lineage cells in bone hematopoiesis. Gaining a deeper insight
into the biology of these cells, especially the regulation of
their differentiation, behaviour, and survival, is valuable. It
may potentially provide a better insight into improving
hematopoietic recovery.
4. Adipogenic Differentiation of Bone Marrow
Mesenchymal Stem Cells and Hematopoiesis
BM adipocytes arise from bone marrow mesenchymal stem
cells [25]. In vitro, differentiation into white adipocytes can
be induced by the addition of insulin, indomethacin, and
dexamethasone to the culture medium [50]. It has been
thought that peroxisome proliferator-activated receptor
gamma (PPARγ) and CCAAT/enhancer-binding protein
alpha (C/EBPα) are the key transcription factors in adipo-
genic differentiation. In adipocytes, PPARγ2 can bind to
the 5′-flanking region of the P2 gene, which is important
for inducing the expression of adipocyte-specific genes and
adipogenic differentiation [51, 52].
As a kind of BM stromal cell, BM adipocytes have been
thought to be just “space-filler” for many years. When hema-
topoietic tissues are damaged, adipocytes expand and result
in the fatty infiltration in the bone marrow [1]. However,
using the transgenic mice, Naveiras et al. first demonstrated
that BM adipocytes are negative regulators in BM hemato-
poiesis under homeostatic and stressed conditions. First, they
found that the number of adipocytes correlates inversely with
the hematopoietic activity in distinct regions of the mouse
BMSC
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Immature osteoblast
Mature osteoblast
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Figure 1: Osteogenesis and hematopoiesis. Distinct cell types in different stages of osteogenic differentiation form unique niches for
hematopoietic cells. Osteoprogenitors secrete IL-7 and IGF-1 to support early-stage B lineage differentiation. Osteoblasts are indispensable
for HSC maintenance. Immature osteoblasts participate in HSC expansion. Mature osteoblasts express DLL4, which binds to Notch
receptor on T cell-competent common lymphoid progenitors (CLP) and induces thymic seeding. Osteocytes conduct lymphoid-
supporting stroma and regulate HSPC mobilization.
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BM. After lethal irradiation, the bone marrow space becomes
replaced by adipocytes. The transgenic mice, mice without
BM fat, showed enhanced hematopoietic recovery postirradi-
ation. Also, pharmacological inhibition of adipogenic differ-
entiation enhanced BM engraftment in wild-type mice [2].
Consistent with that, Lu et al. reported that bonemarrow adi-
pogenesis enhanced by rosiglitazone delayed hematopoietic
recovery, and hematopoietic recovery [53] is improved by
inhibition of adipogenesis following chemotherapy [7].
Those data indicated that BM adipocytes suppress hemato-
poiesis in hematopoietic microenvironment, at least under
stressed conditions. To test this directly, Ambrosi and col-
leagues transplanted fate-committed adipogenic cells into
the tibiae of mice and found a significant reduction in hema-
topoietic progenitor cells in the BM. Taken together, these
data further establish that BM adipocytes significantly atten-
uate hematopoietic regeneration [6]. Here, we review the
negative effect of BM adipocyte on hematopoiesis (Figure 2).
4.1. BM Adipocytes Inhibit Hematopoiesis via Cell-to-Cell
Contact. In earlier studies, Belaid-Choucair et al. showed that
BM adipocytes block granulopoiesis by cell-to-cell contact.
Using an antibody-neutralizing neuropilin-1 (NP-1), they
restored the granulopoiesis of CD34(+) cells. IL-1β and dexa-
methasone also downregulated NP-1 expression and restored
granulopoiesis [54]. In coculture system, adipocytes arrest
HSPCs in the G0 phase of the cell cycle and induce apoptosis
of HSPCs. CXCR4, an indispensable receptor for HSPC
homing and engraftment, is also downregulated on coculture
HSPCs. Silencing of NRP1 in adipocytes restored the CXCR4
expression on HSPCs and rescued the apoptosis of them.
Those data indicated that BM adipocytes inhibit HSPC hom-
ing and engraftment and induce apoptosis of HSPCs via cell-
to-cell contact [55].
4.2. BM Adipocytes Secrete Cytokines and Factors. Adipocytes
differentiated from BMSCs secrete transforming growth fac-
tor β1 (TGF-β1), an inhibitor of hematopoiesis [56]. TGF-β1
mediates cell-cycle arrest of hematopoietic cells by upregulat-
ing p57KIP2 [57]. In vitro, inhibition of TGF-β1 signaling
restored expansion of hematopoietic progenitors in coculture
system [55]. In vivo, inhibition of TGF-β1 signaling acceler-
ates hematopoietic reconstitution after chemotherapy [58]
and rescues BM failure in Fanconi anemia [59].
Lipocalin 2 (LCN2), also a secretory protein of adipocyte,
has an important function in hematopoiesis. In vitro, LCN2
inhibits erythropoiesis by inducing apoptosis and inhibits
differentiation of erythroid progenitors. In vivo, recombinant
LCN2 retards recovery from the anemia in mice being
affected by acute anemia [60, 61]. Elevated plasma LCN2
was significantly associated with anemia in patients with sys-
temic inflammation [62].
Dipeptidyl peptidase-4 (DPP4), produced by adipocytic
lineage [6], cleaves a wide variety of hematopoietic
cytokines and factors, including the chemokine stromal
cell-derived factor-1 (SDF-1), granulocyte-macrophage
colony-stimulating factor (GM-CSF), G-CSF, interleukin-3
(IL-3), and erythropoietin. DPP4 inhibits HSC homing and
engraftment [63] and inhibits hematopoiesis in mice [6].
Inhibition of DPP4 may be a promising strategy to enhance
hematopoietic engraftment and regeneration [64, 65].
4.3. Accumulation of Adipocytes Reduces Blood Flow and
Suppresses Hematopoiesis. Bianco et al. showed that adipo-
genic differentiation of BMSCs resulted in a reduction of
the sinus caliber [66]. This process regulates blood flow and
hematopoietic activity in the BM [67]. When BMSCs are
replaced by adipocytes, sinusoids may be excluded from the
blood flow, because BMSCs are physically associated with
the sinusoid wall. This process is thought to be reversible
because the endothelial wall remains intact. Thus, adipogen-
esis in the BM is thought to be a unique kind of microvascu-
lar pruning to regulate hematopoiesis [68].
5. Differentiation Balance of Mesenchymal
Stem Cells and Hematopoiesis
Over decades of study, accumulating evidence has
demonstrated the reciprocality between osteogenesis and
adipogenesis, which is well documented in [69, 70].
Increased adipogenesis often leads to decreased osteogene-
sis, vice versa [70]. BMSCs are exquisitely balanced for
differentiation commitment.
5.1. Differentiation Bias of BMSCs Exists in Various Stress
Conditions.Many factors, including aging, obesity [6], irradi-
ation [2], and chemotherapy [7], can lead to the differentia-
tion bias of BMSCs. Aging, irradiation, and chemotherapy
are known to cause bone loss and marrow adiposity. In aging,
microenvironmental alterations are predominately responsi-
ble for BMSC lineage switch [71]. Critical microenvironmen-
tal signaling, including transforming growth factor-β (TGF-
β), bone morphogenetic protein (BMP), insulin-like growth
factor-1 (IGF-1), and Wnt signaling, is altered in aging. In
aged mice, TGF-β and BMP signaling were shown to be
altered correlating with reduced osteogenic differentiation
and increased adipogenic differentiation [72]. Also, Wnt3a
and Wnt10b, the Wnt ligands that control osteogenic differ-
entiation, significantly decreased with age [73]. IGF-1, the
growth factor for osteogenesis, was shown to decline with
aging [74]. These microenvironmental alterations may result
in age-related bone loss and marrow adiposity. However, the
mechanism involved in microenvironmental alterations
remains unknown.
The microenvironmental alterations were also observed
in radiation injury. In response to radiation, the marrow
cells, especially T cell, secreted BMP4 to commit BMSCs to
adipogenic lineage [75]. However, the expression of Wnt
ligand in BMSCs, was shown to decrease after radiation
[76]. Xu et al. also demonstrated that dysregulated lympho-
cytes may be responsible for the dysregulation of BMSC
differentiation and subsequent systemic bone loss after local
irradiation [77]. These microenvironmental alterations con-
tributed to the shift of adipo-osteogenic balance of BMSCs.
In addition, other studies also reported that stress
condition-related pathways participated in the shift of
adipo-osteogenic balance of BMSCs. Aging, irradiation, and
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chemotherapy could cause a series of events, including oxida-
tive stress, which activates FOXO signaling [78] and PPARγ
[79]; DNA damage, which activates p53 and p16 pathway
[80–84]; inflammatory factors, which activate nuclear factor
κB (NF-κB) pathway [85–87]; and cellular senescence, which
leads to alteration of senescent-related molecules involved in
differentiation of BMSCs [84, 88]. Unfortunately, most of
these activated pathways were shown to directly regulate
the differentiation of BMSCs and led to the shift of adipo-
osteogenic balance of BMSCs (Figure 3), especially excessive
adipogenesis and attenuated osteogenesis.
Cellular senescence results in the decline of FOXP1
[84] and an increase in miR-188 [88], which correlate
with reduced osteogenic differentiation and increased
adipogenic differentiation.
Senescent cells also showed persistent DNA damage and
telomere dysfunction, which lead to DNA damage response
(DDR) and subsequent activation of the p53 and p16 path-
way [80, 81]. p53 was shown to repress key osteogenic tran-
scriptional factor Osx [82] and inhibit osteogenesis both
in vitro and in vivo [83]. p16 was shown to prevent the phos-
phorylation of pRb, the direct transcriptional coactivator of
Runx2. And loss of p16 partially rescued the osteogenesis of
senescent BMSCs [84].
Under oxidative stress, FOXO signaling is activated to
repress the Wnt signaling and osteogenesis [78]. In addition,
oxidized lipids induced by ROS were shown to activate
PPARγ to suppress osteoblast differentiation and stimulate
adipogenesis [79].
Inflammatory factors [89–91], including TNF-α and
IFN-γ, synergistically impaired osteogenic differentiation in
BMSCs via the NF-κB pathway [85]. Further downstream,
miR-150-3p [87], miR-3077-5p, and miR-705 [86] were
upregulated to mediate the switch from osteogenesis to adi-
pogenesis in BMSCs. TNF-α also activated the NF-κB path-
way to induce oxidative stress in BMSC via miR-705 and in
turn accumulated ROS activated the NF-κB pathway, enter-
ing a positive feedback [92]. These pathways regulate key
transcription factors Runx2 and PPARγ to control the
adipo-osteogenic balance of BMSCs.
5.2. Differentiation Bias of BMSCs Interferes with Bone
Hematopoiesis. Given the critical role of BMSCs and their
progeny in bone hematopoiesis, the differentiation bias of
BMSC
APC
Adipocyte
DPP4
NP-1
TGF-훽1
SDF-1 Microvascular pruning
HSPC
APC
Expansion
Homing
Engrafting
Differentiation
LCN2
HomingHSPCs
HSCT
SDF-1
Hematopoietic recovery
Figure 2: Negative effect of bone marrow adipocytes on hematopoietic recovery. Adipogenic differentiation of bone marrow mesenchymal
stem cells interferes the process of hematopoietic recovery after hematopoietic stem cell transplantation (HSCT). Adipocytic lineage,
including APC (adipogenic progenitor cell), secretes DPP4 to cleave SDF-1. Moreover, BM adipocyte interacts with HSPCs to
downregulate CXCR4 via NP-1, leading to a reduction in SDF-1/CXCR4 signaling and HSPS homing and engrafting. TGF-β1 secreted by
BM adipocyte mediates cell-cycle arrest of HSPCs to inhibit HSPC expansion. Lipocalin 2 secreted by BM adipocyte inhibits
erythropoiesis. DPP4 also cleaves hematopoietic factor including EPO, GM-CSF, G-CSF, and IL-3 to decrease their activity. Furthermore,
BM adipocytes replace BMSCs and “pruning” sinusoids, resulting in a reduction of sinus caliber and hematopoietic activity. “Red” marrow
then becomes “yellow” marrow in BM.
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BMSCs could have the inevitable consequence for bone
hematopoiesis (Figure 4). Excessive adipogenesis and attenu-
ated osteogenesis inhibit bone hematopoietic recovery. Accu-
mulation of BM adipocytes suppressed hematopoietic
recovery in various condition, including aging, obesity [6],
irradiation [2], and chemotherapy [7]. Both deletion of BM
adipocyte and inhibition of BM adipocyte formation pro-
moted hematopoietic recovery [2]. Meanwhile, attenuated
osteogenesis is associated with hematopoietic decline; pro-
moting osteogenesis of BMSCs was also shown to improve
hematopoiesis in irradiation [31] and chemotherapy [93].
Of note, although osteogenesis was shown to promote
hematopoiesis, excessive osteogenesis may impair hemato-
poiesis. In an early study, Calvi et al. demonstrated the posi-
tive correlation between osteoblast lineage cells and HSC
number [31]. However, further study indicated that osteo-
blastic expansion alone is not sufficient to increase HSC
number [41]. In several studies, excessive osteogenesis even
inhibited hematopoiesis. In a transgenic mice model, acti-
vated Gs signaling in osteoblastic lineage cell leads to a mas-
sive increase of bone formation. However, the HSC function
and blood production were impaired [94]. Also, Cock et al.
reported that the absence of PPARγ in mice led to excessive
osteogenesis and reduced BM hematopoiesis [95]. Therefore,
although osteogenesis plays a central role in bone
hematopoiesis, excessive osteogenesis may impair hemato-
poiesis. The mode of activation of osteogenesis is critical.
Interestingly, although excessive adipogenesis was shown
to inhibit hematopoiesis recovery under stress condition, adi-
pogenesis does not always inhibit hematopoiesis. In contrast,
increased hematopoiesis and adipogenesis were observed in
several studies. For example, diet-induced obesity results in
an increase in adipocytes in mouse BM, and hematopoiesis
is enhanced at the same time [96]. What is more, both hema-
topoiesis and adipogenesis are enhanced by the disruption of
TGF-β signaling in Smad3-deficient mice [97]. BM adipose
tissue also acts as an endocrine organ. Adiponectin secreted
by BM adipose tissue enhanced HSC activation [98]. Most
recently, Zhou et al. had found that BM adipocyte-derived
SCF promoted hematopoietic regeneration after irradiation.
And the deletion of SCF in BM adipocytes delayed the hema-
topoietic recovery of mice [99]. These data indicated that BM
adipocytes also produce molecules that benefit hematopoiesis
and that BM adipocytes have both negative and positive
effect on hematopoietic regeneration. But on the whole, the
sum of these effects inhibits hematopoietic recovery under
stress condition [2, 6, 7, 53].
At present, it is still unclear why BM fat has a dual effect
on hematopoiesis. Recently, emerging work has demon-
strated the heterogeneity of BM adipocytes [100]. In different
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Figure 3: Stress condition-related pathways directly interfere with the differentiation of BMSCs. The differentiation of BMSCs is controlled
by a complex signaling network. Runx2 and Osterix are key transcription factors in osteogenic differentiation. And PPARγ and C/EBPα
are key transcription factors in adipogenic differentiation. However, aging, irradiation, and chemotherapy could cause a series of events
and activate subsequent pathways. These pathways regulate key transcription factors Runx2 and PPARγ to lead to the shift of
adipo-osteogenic balance.
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regions of the BM, BM adipocytes have region-specific devel-
opment, regulation, gene expression, lipid composition, and
genetic determinants. They can be divided into rMAT (regu-
lated marrow adipose tissues) and cMAT (constitutive mar-
row adipose tissues) based on their characteristics [100].
The hematopoietic activity is active in the region of rMAT.
But in the region of cMAT, the hematopoietic activity is very
low [2, 99]. These data suggested the possibility that different
BM adipocytes may have a different effect on hematopoiesis,
and the heterogeneity of BM adipocytes may lead to the dual
effect. Although this idea is attractive, much work is needed
to be done. With transgenic mice model [100], this problem
could be solved in further studies. On the whole, inhibiting
the BM fat formation was shown to promote hematopoietic
recovery in animal models [2, 6, 7, 53].
Taken together, although early studies suggested that
osteogenesis of BMSCs promotes hematopoiesis and adipo-
genesis of BMSCs negatively regulates hematopoiesis, recent
studies indicated that both excessive adipogenesis and osteo-
genesis could impair hematopoiesis. Keeping the adipo-
osteogenic balance of BMSCs is therefore crucial to bone
hematopoiesis. Rescuing the dysregulation of BMSC differ-
entiation could be a promising strategy for hematopoietic
recovery in various conditions.
5.3. Promoting Hematopoietic Recovery by Rescuing
Differentiation Bias of BMSCs. Differentiation biases of
BMSCs, especially excessive adipogenesis and attenuated
osteogenesis, were shown to inhibit bone hematopoietic
recovery [2, 6, 7]. In animal experiments, pharmaceutical
interventions that rescue differentiation bias of BMSCs were
shown to promote hematopoietic recovery (Table 1).
BADGE, a PPARγ inhibitor, is a strong inhibitor of adi-
pogenesis of BMSCs [101]. This synthetic compound can
bind to PPARγ, the key transcription factor in adipogenesis,
and inhibit its activities. It was shown to inhibit adipogenesis
in vitro an in vivo [2]. After irradiation and BMT, the
administration of BADGE significantly inhibited BM fat for-
mation and promoted hematopoietic recovery in mice [2].
After high-dose chemotherapy, BADGE treatment acceler-
ated the recovery of leukocyte count and number of HSCs in
mice [7]. Also, BADGE treatment reduced the rosiglitazone-
induced BM fat formation and promoted hematopoietic
recovery under hematopoietic stress in mice [53]. These
studies indicated that inhibiting adipogenesis of BMSCs could
be an effective strategy to promote hematopoietic recovery.
Moreover, promoting the osteogenesis of BMSCs was
also shown to enhance hematopoietic recovery. Osteogenic
differentiation can be induced in vitro by bone morphoge-
netic proteins (BMPs) [26] or by a differentiation cocktail
of ascorbate, dexamethasone, and β-glycerophosphate [27].
Osteogenesis-inducing cocktails (OICS) are known to
enhance the activity and expression of Runx2, the key tran-
scription factor in osteogenesis, and promote osteogenesis
of BMSCs [102]. After lethal irradiation and BMT, the OICS
treatment was shown to promote the hematopoietic recovery
and survival of mice [103].
PTH is a critical regulator of calcium homeostasis
and osteogenesis. Mechanistically, PTH was proposed to
enhance the osteogenesis of BMSCs by promoting the
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Figure 4: Differentiation balance of mesenchymal stem cells and hematopoiesis. There is a reciprocality between osteogenesis and
adipogenesis. Increased adipogenesis often leads to decreased osteogenesis, vice versa. BMSCs are exquisitely balanced for differentiation
commitment. Modest osteogenesis of BMSCs promotes hematopoiesis. However, excessive adipogenesis impairs hematopoiesis. Keeping
the adipo-osteogenic balance of BMSCs is therefore essential to bone hematopoiesis.
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phosphorylation of Smad1/5/8, which are key factors in
BMP signaling [104].
It was shown to promote osteogenic differentiation of
BMSCs in vivo and in vitro. After myeloablative BMT, intra-
peritoneal injection of rat PTH for 4 weeks significantly
improved hematopoietic engrafting and survival of mice
[31]. Also, after multiple rounds of chemotherapy, PTH
treatment protected hematopoiesis and preserved the HSC
pool in mice [93]. These studies indicated that promoting
the osteogenesis of BMSCs could also be an effective strategy
to promote hematopoietic recovery.
Taken together, rescuing the dysregulation of BMSC dif-
ferentiation could be a promising strategy for hematopoietic
recovery in various conditions.
6. Conclusion and Perspectives
Larger progress has been made to understand the relation-
ship between BMSC differentiation and hematopoiesis. Oste-
ogenesis of BMSCs plays a central role in hematopoiesis,
while adipogenesis of BMSCs has a negative effect on hema-
topoietic recovery. The adipo-osteogenic balance of BMSCs
is exquisitely balanced. Many factors, including aging, obe-
sity, irradiation, and chemotherapy, can lead to the differen-
tiation bias of BMSCs and related hematopoietic disorder.
Rescuing the dysregulation of BMSC differentiation is crucial
to bone hematopoietic recovery. However, there are several
questions that remain to be answered.
First, what is the key mechanism that couples osteo-
genesis and HSC expansion? Early studies reported
parathyroid hormone receptor signaling in osteoblast is
responsible for the increase in HSC number [31] and
indicated that increased expression of Jagged-1 and N-
cadherin in osteoblasts is associated with HSC expansion
[31]. However, further studies failed to support this idea
[105, 106]. Although it was reported that the immature
osteoblast may play a role in HSC expansion and mainte-
nance [45, 46], the key molecular mechanisms still remain
largely unknown.
Second, given that the osteoblast lineage cells are
critical for T and B cell development [36], is attenuated
osteogenesis a cause for aging- and obesity-related
immune decline? Is the inhibition of osteogenesis a barrier
for immune recovery after radiation and chemotherapy?
Could it be a strategy to improve immune recovery by
promoting osteogenesis?
Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this article.
Authors’ Contributions
JiangWu andWeiwei Zhang contributed equally to this work
and should be considered co-first authors.
Acknowledgments
This study was supported by the National Natural Science
Foundation of China (no. 81472915), the National Natural
Youth Science Foundation of China (no. 81402634), and
the Youth Scientist Foundation of Chongqing (CSTC
2013JCYJJQ10001).
References
[1] F. Snyder, “Fatty acid oxidation in irradiated bone marrow
cells,” Nature, vol. 206, no. 4985, p. 733, 1965.
[2] O. Naveiras, V. Nardi, P. L. Wenzel, P. V. Hauschka, F. Fahey,
and G. Q. Daley, “Bone-marrow adipocytes as negative regu-
lators of the haematopoietic microenvironment,” Nature,
vol. 460, no. 7252, pp. 259–263, 2009.
[3] R. Sugimura and L. H. Li, “Shifting in balance between oste-
ogenesis and adipogenesis substantially influences hemato-
poiesis,” Journal of Molecular Cell Biology, vol. 2, no. 2,
pp. 61-62, 2010.
[4] P. Bianco, “"Mesenchymal" stem cells,” Annual Review of Cell
and Developmental Biology, vol. 30, no. 1, pp. 677–704, 2014.
[5] M. Bethel, B. R. Chitteti, E. F. Srour, and M. A. Kacena, “The
changing balance between osteoblastogenesis and adipogene-
sis in aging and its impact on hematopoiesis,” Current Osteo-
porosis Reports, vol. 11, no. 2, pp. 99–106, 2013.
[6] T. H. Ambrosi, A. Scialdone, A. Graja et al., “Adipocyte accu-
mulation in the bone marrow during obesity and aging
impairs stem cell-based hematopoietic and bone regenera-
tion,” Cell Stem Cell, vol. 20, no. 6, pp. 771–784.e6, 2017.
[7] R. J. Zhu, M. Q. Wu, Z. J. Li, Y. Zhang, and K. Y. Liu, “Hema-
topoietic recovery following chemotherapy is improved by
BADGE-induced inhibition of adipogenesis,” International
Journal of Hematology, vol. 97, no. 1, pp. 58–72, 2013.
[8] J. Kobolak, A. Dinnyes, A. Memic, A. Khademhosseini, and
A. Mobasheri, “Mesenchymal stem cells: identification, phe-
notypic characterization, biological properties and potential
for regenerative medicine through biomaterial micro-
engineering of their niche,”Methods, vol. 99, pp. 62–68, 2016.
Table 1: Promoting hematopoietic recovery by rescuing differentiation bias of BMSCs.
Targets Model Animal Agent Dose Route Duration Hematopoietic recovery Reference
PPARγ Radiation Mice BADGE 30mg/kg/d Intraperitoneal injection 2 weeks ↑ WBC, ↑ CFU [2]
PPARγ Chemotherapy Mice BADGE 60mg/kg/d Intraperitoneal injection 4 weeks ↑ WBC, ↑ HSCs [7]
PPARγ Chemotherapy Mice BADGE 60mg/kg/d Intraperitoneal injection 2 weeks ↑ WBC, ↑ CMP, ↑ GMP [53]
Runx2 Radiation Mice OICS — Intraperitoneal injection 1 week ↑ WBC, ↑ Hb [103]
BMP signaling Radiation Mice PTH 80 μg/kg/d Intraperitoneal injection 4 weeks ↑ HSCs, ↑ CFU [31]
BMP signaling Chemotherapy Mice PTH 80 μg/kg/d Intraperitoneal injection 2 weeks ↑ HSCs [93]
9Stem Cells International
[9] P. Flores-Guzman, E. Flores-Figueroa, J. J. Montesinos et al.,
“Individual and combined effects of mesenchymal stromal
cells and recombinant stimulatory cytokines on the in vitro
growth of primitive hematopoietic cells from human umbili-
cal cord blood,” Cytotherapy, vol. 11, no. 7, pp. 886–896,
2009.
[10] A. J. Friedenstein, S. Piatetzky II, and K. V. Petrakova, “Oste-
ogenesis in transplants of bone marrow cells,” Journal of
Embryology and Experimental Morphology, vol. 16, no. 3,
pp. 381–390, 1966.
[11] B. Sacchetti, A. Funari, S. Michienzi et al., “Self-renewing
osteoprogenitors in bone marrow sinusoids can organize a
hematopoietic microenvironment,” Cell, vol. 133, no. 5,
pp. 928–928, 2008.
[12] T. Sugiyama, H. Kohara, M. Noda, and T. Nagasawa, “Main-
tenance of the hematopoietic stem cell pool by CXCL12-
CXCR4 chemokine signaling in bone marrow stromal cell
niches,” Immunity, vol. 25, no. 6, pp. 977–988, 2006.
[13] S. Mendez-Ferrer, T. V. Michurina, F. Ferraro et al., “Mesen-
chymal and haematopoietic stem cells form a unique bone
marrow niche,”Nature, vol. 466, no. 7308, pp. 829–834, 2010.
[14] L. Ding, T. L. Saunders, G. Enikolopov, and S. J. Morrison,
“Endothelial and perivascular cells maintain haematopoietic
stem cells,” Nature, vol. 481, no. 7382, pp. 457–462, 2012.
[15] A. Greenbaum, Y. M. S. Hsu, R. B. Day et al., “CXCL12 in
early mesenchymal progenitors is required for haematopoie-
tic stem-cell maintenance,” Nature, vol. 495, no. 7440,
pp. 227–230, 2013.
[16] A. Mendelson and P. S. Frenette, “Hematopoietic stem cell
niche maintenance during homeostasis and regeneration,”
Nature Medicine, vol. 20, no. 8, pp. 833–846, 2014.
[17] Y. Omatsu, T. Sugiyama, H. Kohara et al., “The essential
functions of adipo-osteogenic progenitors as the hematopoi-
etic stem and progenitor cell niche,” Immunity, vol. 33, no. 3,
pp. 387–399, 2010.
[18] L. Ding and S. J. Morrison, “Haematopoietic stem cells and
early lymphoid progenitors occupy distinct bone marrow
niches,” Nature, vol. 495, no. 7440, pp. 231–235, 2013.
[19] Y. Kunisaki, I. Bruns, C. Scheiermann et al., “Arteriolar
niches maintain haematopoietic stem cell quiescence,”
Nature, vol. 502, no. 7473, pp. 637–643, 2013.
[20] P. Flores-Guzman, V. Fernandez-Sanchez, and H. Mayani,
“Concise review: ex vivo expansion of cord blood-derived
hematopoietic stem and progenitor cells: basic principles,
experimental approaches, and impact in regenerative medi-
cine,” Stem Cells Translational Medicine, vol. 2, no. 11,
pp. 830–838, 2013.
[21] F. Dazzi, R. Ramasamy, S. Glennie, S. P. Jones, and I. Roberts,
“The role of mesenchymal stem cells in haemopoiesis,” Blood
Reviews, vol. 20, no. 3, pp. 161–171, 2006.
[22] T. Mizoguchi, S. Pinho, J. Ahmed et al., “Osterix marks dis-
tinct waves of primitive and definitive stromal progenitors
during bone marrow development,” Developmental Cell,
vol. 29, no. 3, pp. 340–349, 2014.
[23] A. D. Berendsen and B. R. Olsen, “Bone development,” Bone,
vol. 80, pp. 14–18, 2015.
[24] F. Santagati and F. M. Rijli, “Cranial neural crest and the
building of the vertebrate head,” Nature Reviews Neurosci-
ence, vol. 4, no. 10, pp. 806–818, 2003.
[25] B. O. Zhou, R. Yue, M. M. Murphy, J. G. Peyer, and S. J.
Morrison, “Leptin-receptor-expressing mesenchymal stromal
cells represent the main source of bone formed by adult bone
marrow,” Cell Stem Cell, vol. 15, no. 2, pp. 154–168, 2014.
[26] C. Banerjee, A. Javed, J. Y. Choi et al., “Differential regulation
of the two principal Runx2/Cbfa1 n-terminal isoforms in
response to bone morphogenetic protein-2 during develop-
ment of the osteoblast phenotype,” Endocrinology, vol. 142,
no. 9, pp. 4026–4039, 2001.
[27] N. Jaiswal, S. E. Haynesworth, A. I. Caplan, and S. P. Bruder,
“Osteogenic differentiation of purified, culture-expanded
human mesenchymal stem cells in vitro,” Journal of Cellular
Biochemistry, vol. 64, no. 2, pp. 295–312, 1997.
[28] F. Otto, A. P. Thornell, T. Crompton et al., “Cbfa1, a candi-
date gene for cleidocranial dysplasia syndrome, is essential
for osteoblast differentiation and bone development,” Cell,
vol. 89, no. 5, pp. 765–771, 1997.
[29] H. Zheng, Z. Guo, Q. Ma, H. Jia, and G. Dang, “Cbfa1/osf2
transduced bone marrow stromal cells facilitate bone forma-
tion in vitro and in vivo,” Calcified Tissue International,
vol. 74, no. 2, pp. 194–203, 2004.
[30] R. S. Taichman, M. J. Reilly, and S. G. Emerson, “Human
osteoblasts support human hematopoietic progenitor cells
in vitro bone marrow cultures,” Blood, vol. 87, no. 2,
pp. 518–524, 1996.
[31] L. M. Calvi, G. B. Adams, K. W. Weibrecht et al., “Osteoblas-
tic cells regulate the haematopoietic stem cell niche,” Nature,
vol. 425, no. 6960, pp. 841–846, 2003.
[32] D. Visnjic, Z. Kalajzic, D. W. Rowe, V. Katavic, J. Lorenzo,
and H. L. Aguila, “Hematopoiesis is severely altered in mice
with an induced osteoblast deficiency,” Blood, vol. 103,
no. 9, pp. 3258–3264, 2004.
[33] C. Panaroni, K. Fulzele, V. Saini, R. Chubb, P. D. Pajevic, and
J. Y. Wu, “PTH signaling in osteoprogenitors is essential for
B-lymphocyte differentiation and mobilization,” Journal of
Bone and Mineral Research, vol. 30, no. 12, pp. 2273–2286,
2015.
[34] T. Nagasawa, “Microenvironmental niches in the bone mar-
row required for B-cell development,”Nature Reviews Immu-
nology, vol. 6, no. 2, pp. 107–116, 2006.
[35] J. Y. Wu, L. E. Purton, S. J. Rodda et al., “Osteoblastic regula-
tion of B lymphopoiesis is mediated by Gsα-dependent
signaling pathways,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 105, no. 44,
pp. 16976–16981, 2008.
[36] V. W. C. Yu, S. Lymperi, T. Oki et al., “Distinctive
mesenchymal-parenchymal cell pairings govern B cell differ-
entiation in the bone marrow,” Stem Cell Reports, vol. 7, no. 2,
pp. 220–235, 2016.
[37] H. L. Aguila, S. H. Mun, J. Kalinowski, D. J. Adams, J. A.
Lorenzo, and S. K. Lee, “Osteoblast-specific overexpression
of human interleukin-7 rescues the bone mass phenotype
of interleukin-7-deficient female mice,” Journal of Bone
and Mineral Research, vol. 27, no. 5, pp. 1030–1042, 2012.
[38] S. C. De Barros, V. S. Zimmermann, and N. Taylor, “Concise
review: hematopoietic stem cell transplantation: targeting the
thymus,” Stem Cells, vol. 31, no. 7, pp. 1245–1251, 2013.
[39] D. A. Zlotoff, S. L. Zhang, M. E. De Obaldia et al., “Delivery of
progenitors to the thymus limits T-lineage reconstitution
after bone marrow transplantation,” Blood, vol. 118, no. 7,
pp. 1962–1970, 2011.
[40] V. W. C. Yu, B. Saez, C. Cook et al., “Specific bone cells
produce DLL4 to generate thymus-seeding progenitors from
10 Stem Cells International
bone marrow,” Journal of Experimental Medicine, vol. 212,
no. 5, pp. 759–774, 2015.
[41] L. M. Calvi, O. Bromberg, Y. Rhee et al., “Osteoblastic expan-
sion induced by parathyroid hormone receptor signaling in
murine osteocytes is not sufficient to increase hematopoietic
stem cells,” Blood, vol. 119, no. 11, pp. 2489–2499, 2012.
[42] S. J. Morrison and D. T. Scadden, “The bone marrow niche
for haematopoietic stem cells,” Nature, vol. 505, no. 7483,
pp. 327–334, 2014.
[43] E.Roeder, B.G.Matthews, and I.Kalajzic, “Visual reporters for
study of the osteoblast lineage,” Bone, vol. 92, pp. 189–195,
2016.
[44] B. R. Chitteti, Y. H. Cheng, D. A. Streicher et al., “Osteoblast
lineage cells expressing high levels of Runx2 enhance
hematopoietic progenitor cell proliferation and function,”
Journal of Cellular Biochemistry, vol. 111, no. 2, pp. 284–
294, 2010.
[45] B. R. Chitteti, Y. H. Cheng, M. A. Kacena, and E. F. Srour,
“Hierarchical organization of osteoblasts reveals the signifi-
cant role of CD166 in hematopoietic stem cell maintenance
and function,” Bone, vol. 54, no. 1, pp. 58–67, 2013.
[46] B. R. Chitteti, M. Kobayashi, Y. Cheng et al., “CD166 regu-
lates human and murine hematopoietic stem cells and the
hematopoietic niche,” Blood, vol. 124, no. 4, pp. 519–529,
2014.
[47] L. F. Bonewald, “The role of the osteocyte in bone and
nonbone disease,” Endocrinology and Metabolism Clinics of
North America, vol. 46, no. 1, pp. 1–18, 2017.
[48] M. Sato, N. Asada, Y. Kawano et al., “Osteocytes regulate
primary lymphoid organs and fat metabolism,” Cell Metabo-
lism, vol. 18, no. 5, pp. 749–758, 2013.
[49] N. Asada, Y. Katayama, M. Sato et al., “Matrix-embedded
osteocytes regulate mobilization of hematopoietic stem/pro-
genitor cells,” Cell Stem Cell, vol. 12, no. 6, pp. 737–747, 2013.
[50] A. Pansky, B. Roitzheim, and E. Tobiasch, “Differentiation
potential of adult human mesenchymal stem cells,” Clinical
Laboratory, vol. 53, no. 1-2, pp. 81–84, 2007.
[51] P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M.
Spiegelman, “mPPAR gamma 2: tissue-specific regulator of
an adipocyte enhancer,” Genes & Development, vol. 8,
no. 10, pp. 1224–1234, 1994.
[52] Z. Wu, E. D. Rosen, R. Brun et al., “Cross-regulation of
C/EBPα and PPARγ controls the transcriptional pathway
of adipogenesis and insulin sensitivity,” Molecular Cell,
vol. 3, no. 2, pp. 151–158, 1999.
[53] W. Lu, W. Wang, S. Wang, Y. Feng, and K. Liu, “Rosiglita-
zone promotes bone marrow adipogenesis to impair myelo-
poiesis under stress,” PLoS One, vol. 11, no. 2, article
e0149543, 2016.
[54] Z. Belaid-Choucair, Y. Lepelletier, G. Poncin et al., “Human
bone marrow adipocytes block granulopoiesis through
neuropilin-1-induced granulocyte colony-stimulating factor
inhibition,” Stem Cells, vol. 26, no. 6, pp. 1556–1564, 2008.
[55] S. S. Ghode, M. S. Bajaj, R. S. Kulkarni, L. S. Limaye, Y. S.
Shouche, and V. P. Kale, “Neuropilin-1 is an important niche
component and exerts context-dependent effects on hemato-
poietic stem cells,” Stem Cells and Development, vol. 26, no. 1,
pp. 35–48, 2017.
[56] E. Sitnicka, F. W. Ruscetti, G. V. Priestley, N. S. Wolf, and
S. H. Bartelmez, “Transforming growth factor beta 1 directly
and reversibly inhibits the initial cell divisions of long-term
repopulating hematopoietic stem cells,” Blood, vol. 88, no. 1,
pp. 82–88, 1996.
[57] J. M. Scandura, P. Boccuni, J. Massague, and S. D. Nimer,
“Transforming growth factor β-induced cell cycle arrest of
human hematopoietic cells requires p57KIP2 up-regula-
tion,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 101, no. 42, pp. 15231–
15236, 2004.
[58] F. Brenet, P. Kermani, R. Spektor, S. Rafii, and J. M. Scandura,
“TGFβ restores hematopoietic homeostasis after myelosup-
pressive chemotherapy,” Journal of Experimental Medicine,
vol. 210, no. 3, pp. 623–639, 2013.
[59] H. J. Zhang, D. E. Kozono, K. W. O'Connor et al., “TGF-β
inhibition rescues hematopoietic stem cell defects and bone
marrow failure in Fanconi anemia,” Cell Stem Cell, vol. 18,
no. 5, pp. 668–681, 2016.
[60] K. Miharada, T. Hiroyama, K. Sudo, T. Nagasawa, and
Y. Nakamura, “Lipocalin 2 functions as a negative regulator
of red blood cell production in an autocrine fashion,” FASEB
Journal, vol. 19, no. 13, pp. 1881–1883, 2005.
[61] K. Miharada, T. Hiroyama, K. Sudo, I. Danjo, T. Nagasawa,
and Y. Nakamura, “Lipocalin 2-mediated growth suppression
is evident in human erythroid and monocyte/macrophage
lineage cells,” Journal of Cellular Physiology, vol. 215, no. 2,
pp. 526–537, 2008.
[62] J. W. Choi, T. Fujii, and N. Fujii, “Elevated plasma neutrophil
gelatinase-associated lipocalin level as a risk factor for anemia
in patients with systemic inflammation,” BioMed Research
International, vol. 2016, Article ID 9195219, 8 pages,
2016.
[63] H. E. Broxmeyer, J. Hoggatt, H. A. O'Leary et al., “Dipeptidyl-
peptidase 4 negatively regulates colony-stimulating factor
activity and stress hematopoiesis,” Nature Medicine, vol. 18,
no. 12, pp. 1786–1796, 2012.
[64] S. S. Farag, S. Srivastava, S. Messina-Graham et al., “In vivo
DPP-4 inhibition to enhance engraftment of single-unit cord
blood transplants in adults with hematological malignancies,”
Stem Cells and Development, vol. 22, no. 7, pp. 1007–1015,
2013.
[65] T. C. Lund, A. E. Boitano, C. S. Delaney, E. J. Shpall, and J. E.
Wagner, “Advances in umbilical cord blood manipulation-
from niche to bedside,” Nature Reviews Clinical Oncology,
vol. 12, no. 3, pp. 163–174, 2015.
[66] P. Bianco, M. Costantini, L. C. Dearden, and E. Bonucci,
“Alkaline phosphatase positive precursors of adipocytes in
the human bone marrow,” British Journal of Haematology,
vol. 68, no. 4, pp. 401–403, 1988.
[67] P. Bianco and P. G. Robey, “Skeletal stem cells,”Development,
vol. 142, no. 6, pp. 1023–1027, 2015.
[68] P. Bianco, “Bone and the hematopoietic niche: a tale of two
stem cells,” Blood, vol. 117, no. 20, pp. 5281–5288, 2011.
[69] E. Rendina-Ruedy and C. J. Rosen, “Bone-fat interaction,”
Endocrinology and Metabolism Clinics of North America,
vol. 46, no. 1, pp. 41–50, 2017.
[70] Q. Chen, P. Shou, C. Zheng et al., “Fate decision of mesenchy-
mal stem cells: adipocytes or osteoblasts?,” Cell Death and
Differentiation, vol. 23, no. 7, pp. 1128–1139, 2016.
[71] L. Singh, T. A. Brennan, E. Russell et al., “Aging alters bone-
fat reciprocity by shifting in vivo mesenchymal precursor cell
fate towards an adipogenic lineage,” Bone, vol. 85, pp. 29–36,
2016.
11Stem Cells International
[72] E. J. Moerman, K. Teng, D. A. Lipschitz, and B. Lecka-
Czernik, “Aging activates adipogenic and suppresses osteo-
genic programs in mesenchymal marrow stroma/stem cells:
the role of PPAR-γ2 transcription factor and TGF-β/BMP
signaling pathways,” Aging Cell, vol. 3, no. 6, pp. 379–389,
2004.
[73] M. Rauner, W. Sipos, and P. Pietschmann, “Age-dependent
Wnt gene expression in bone and during the course of
osteoblast differentiation,” Age, vol. 30, no. 4, pp. 273–282,
2008.
[74] L. L. Xian, X. W. Wu, L. J. Pang et al., “Matrix IGF-1 main-
tains bonemass by activation of mTOR inmesenchymal stem
cells,” Nature Medicine, vol. 18, no. 7, pp. 1095–1101, 2012.
[75] M. S. Bajaj, R. S. Kulkarni, S. S. Ghode, L. S. Limaye, and V. P.
Kale, “Irradiation-induced secretion of BMP4 by marrow
cells causes marrow adipogenesis post-myelosuppression,”
Stem Cell Research, vol. 17, no. 3, pp. 646–653, 2016.
[76] M. S. Islam, M. E. Stemig, Y. Takahashi, and S. K. Hui, “Radi-
ation response of mesenchymal stem cells derived from bone
marrow and human pluripotent stem cells,” Journal of Radi-
ation Research, vol. 56, no. 2, pp. 269–277, 2015.
[77] X. Xu, R. Li, Y. Zhou et al., “Dysregulated systemic lympho-
cytes affect the balance of osteogenic/adipogenic differentia-
tion of bone mesenchymal stem cells after local irradiation,”
Stem Cell Research & Therapy, vol. 8, no. 1, p. 71, 2017.
[78] S. Iyer, E. Ambrogini, S. M. Bartell et al., “FOXOs attenuate
bone formation by suppressing Wnt signaling,” Journal of
Clinical Investigation, vol. 123, no. 8, pp. 3409–3419, 2013.
[79] Y. Tintut and L. L. Demer, “Effects of bioactive lipids and
lipoproteins on bone,” Trends in Endocrinology and Metabo-
lism, vol. 25, no. 2, pp. 53–59, 2014.
[80] J. N. Farr, D. G. Fraser, H.Wang et al., “Identification of senes-
cent cells in the bonemicroenvironment,” Journal of Bone and
Mineral Research, vol. 31, no. 11, pp. 1920–1929, 2016.
[81] N. H. Nicolay, R. L. Perez, R. Saffrich, and P. E. Huber,
“Radio-resistant mesenchymal stem cells: mechanisms of
resistance and potential implications for the clinic,” Oncotar-
get, vol. 6, no. 23, pp. 19366–19380, 2015.
[82] X. Y. Wang, H. Y. Kua, Y. Y. Hu et al., “p53 functions as a
negative regulator of osteoblastogenesis, osteoblast-
dependent osteoclastogenesis, and bone remodeling,” Journal
of Cell Biology, vol. 172, no. 1, pp. 115–125, 2006.
[83] W. J. Liu, M. Qi, A. Konermann, L. Q. Zhang, F. Jin, and
Y. Jin, “The p53/miR-17/Smurf1 pathway mediates skeletal
deformities in an age-related model via inhibiting the func-
tion of mesenchymal stem cells,” Aging, vol. 7, no. 3,
pp. 205–218, 2015.
[84] H. Li, P. Liu, S. Xu et al., “FOXP1 controls mesenchymal stem
cell commitment and senescence during skeletal aging,”
The Journal of Clinical Investigation, vol. 127, no. 4,
pp. 1241–1253, 2017.
[85] L. Wang, Y. Zhao, Y. Liu et al., “IFN-γ and TNF-α synergis-
tically induce mesenchymal stem cell impairment and tumor-
igenesis via NFκB signaling,” Stem Cells, vol. 31, no. 7,
pp. 1383–1395, 2013.
[86] L. Liao, X. Yang, X. Su et al., “Redundant miR-3077-5p and
miR-705 mediate the shift of mesenchymal stem cell lineage
commitment to adipocyte in osteoporosis bone marrow,” Cell
Death & Disease, vol. 4, no. 4, article e600, 2013.
[87] N. Wang, Z. Zhou, T. Wu et al., “TNF-α-induced NF-κB
activation upregulates microRNA-150-3p and inhibits
osteogenesis of mesenchymal stem cells by targeting β-
catenin,” Open Biology, vol. 6, no. 3, 2016.
[88] C. J. Li, P. Cheng, M. K. Liang et al., “MicroRNA-188
regulates age-related switch between osteoblast and adipocyte
differentiation,” Journal of Clinical Investigation, vol. 125,
no. 4, pp. 1509–1522, 2015.
[89] G. Pawelec, D. Goldeck, and E. Derhovanessian, “Inflamma-
tion, ageing and chronic disease,” Current Opinion in Immu-
nology, vol. 29, pp. 23–28, 2014.
[90] S. A. Lorimore, P. J. Coates, G. E. Scobie, G. Milne, and
E. G. Wright, “Inflammatory-type responses after exposure
to ionizing radiation in vivo: a mechanism for radiation-
induced bystander effects?,” Oncogene, vol. 20, no. 48,
pp. 7085–7095, 2001.
[91] H. Lu, S. Zhu, L. Qian et al., “Activated expression of
the chemokine Mig after chemotherapy contributes to
chemotherapy-induced bone marrow suppression and lethal
toxicity,” Blood, vol. 119, no. 21, pp. 4868–4877, 2012.
[92] L. Liao, X. Su, X. Yang et al., “TNF-α inhibits FoxO1 by
upregulating miR-705 to aggravate oxidative damage in bone
marrow-derived mesenchymal stem cells during osteoporo-
sis,” Stem Cells, vol. 34, no. 4, pp. 1054–1067, 2016.
[93] S. Li, D. Zou, C. Li et al., “Targeting stem cell niche can pro-
tect hematopoietic stem cells from chemotherapy and G-CSF
treatment,” Stem Cell Research & Therapy, vol. 6, no. 1,
p. 175, 2015.
[94] K. Schepers, E. C. Hsiao, T. Garg, M. J. Scott, and E. Passegue,
“Activated Gs signaling in osteoblastic cells alters the hemato-
poietic stem cell niche in mice,” Blood, vol. 120, no. 17,
pp. 3425–3435, 2012.
[95] T. A. Cock, J. Back, F. Elefteriou et al., “Enhanced bone for-
mation in lipodystrophic PPARγhyp/hyp mice relocates hae-
matopoiesis to the spleen,” EMBO Reports, vol. 5, no. 10,
pp. 1007–1012, 2004.
[96] M. D. Trottier, A. Naaz, Y. Li, and P. J. Fraker, “Enhancement
of hematopoiesis and lymphopoiesis in diet-induced
obese mice,” Proceedings of the National Academy of Sci-
ences of the United States of America, vol. 109, no. 20,
pp. 7622–7629, 2012.
[97] M. W. Epperly, S. Cao, J. Goff et al., “Increased longevity
of hematopoiesis in continuous bone marrow cultures
and adipocytogenesis in marrow stromal cells derived from
Smad3
−/− mice,” Experimental Hematology, vol. 33, no. 3,
pp. 353–362, 2005.
[98] Y. Masamoto, S. Arai, T. Sato et al., “Adiponectin enhances
quiescence exit of murine hematopoietic stem cells and
hematopoietic recovery through mTORC1 potentiation,”
Stem Cells, vol. 35, no. 7, pp. 1835–1848, 2017.
[99] B. O. Zhou, H. Yu, R. Yue et al., “Bone marrow adipocytes
promote the regeneration of stem cells and haematopoiesis
by secreting SCF,” Nature Cell Biology, vol. 19, no. 8,
pp. 891–903, 2017.
[100] E. L. Scheller, C. R. Doucette, B. S. Learman et al.,
“Region-specific variation in the properties of skeletal adi-
pocytes reveals regulated and constitutive marrow adipose
tissues,” Nature Communications, vol. 6, no. 1, p. 7808,
2015.
[101] H. M. Wright, C. B. Clish, T. Mikami et al., “A synthetic
antagonist for the peroxisome proliferator-activated receptor
gamma inhibits adipocyte differentiation,” The Journal of
Biological Chemistry, vol. 275, no. 3, pp. 1873–1877, 2000.
12 Stem Cells International
[102] F. Langenbach and J. Handschel, “Effects of dexamethasone,
ascorbic acid and β-glycerophosphate on the osteogenic
differentiation of stem cells in vitro,” Stem Cell Research &
Therapy, vol. 4, no. 5, p. 117, 2013.
[103] N. Sugino, Y. Miura, H. Yao et al., “Early osteoinductive
human bone marrow mesenchymal stromal/stem cells
support an enhanced hematopoietic cell expansion with
altered chemotaxis- and adhesion-related gene expression
profiles,” Biochemical and Biophysical Research Communica-
tions, vol. 469, no. 4, pp. 823–829, 2016.
[104] B. Yu, X. L. Zhao, C. Z. Yang et al., “Parathyroid hormone
induces differentiation of mesenchymal stromal/stem cells
by enhancing bone morphogenetic protein signaling,”
Journal of Bone and Mineral Research, vol. 27, no. 9,
pp. 2001–2014, 2012.
[105] O. Bromberg, B. J. Frisch, J. M. Weber, R. L. Porter,
R. Civitelli, and L. M. Calvi, “Osteoblastic N-cadherin is not
required for microenvironmental support and regulation of
hematopoietic stem and progenitor cells,” Blood, vol. 120,
no. 2, pp. 303–313, 2012.
[106] S. J. C. Mancini, N. Mantei, A. Dumortier, U. Suter, H. R.
MacDonald, and F. Radtke, “Jagged1-dependent Notch
signaling is dispensable for hematopoietic stem cell self-
renewal and differentiation,” Blood, vol. 105, no. 6,
pp. 2340–2342, 2005.
13Stem Cells International
